Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NextPharma Acquires Santen’s Tampere Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

NextPharma Acquires Santen’s Tampere Mfg. Facility

Adds ophthalmology manufacturing and sterile blow, fill, seal technology to its portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

NextPharma, a European contract development and manufacturing organization (CDMO), has acquired a manufacturing facility in Tampere, Finland from Santen SA.
 
The acquisition is expected to be completed in the summer of 2019. The companies are entering into a strategic partnership that will see NextPharma take over production of Santen products in the Tampere facility.
 
NextPharma will be taking over the fully staffed site with 181 employees involved in manufacturing and its support functions, including quality control, quality assurance, IT and administration. A large number of Santen employees in Finland not necessarily linked to manufacturing or its functions, such as sales and marketing, R&D, regulatory, quality assurance, pharmacovigilance, human resources, IT and administration will not be affected by the acquisition.
 
“Since 1997, Santen has benefited tremendously from the expertise and commitment of our colleagues here in Tampere, which has contributed so significantly to the growth of the Santen business in the region,” said Katri Outinen, managing director, Santen Oy. “We are pleased that through the acquisition of the site by NextPharma, we both increase the flexibility and efficiency for Santen’s supply chain and at the same time generate an exciting future for our people by becoming the center of excellence for ophthalmology and blow fill seal technology (BFS) within the NextPharma manufacturing network. Santen’s goal of securing sustainable growth as a specialized pharmaceutical company with a global presence is now one step closer.”
 
Peter Burema, chief executive officer, NextPharma, said, “This is an important
moment for NextPharma as a leading European CDMO. Through this acquisition, Tampere will add ophthalmology manufacturing and sterile BFS technology and will provide an excellent extension to our six other manufacturing sites in Europe, each of them with their own specific technologies and/or therapeutic classes of medicine. The extensive experience that the Santen team will bring is key to the continuity of production of the highest quality products, and we are eager to welcome them to the NextPharma family.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics